Hypothesis

Combining low-dose rapamycin with an AMPK activator (e.g., metformin) will reproduce the full metabolic shift seen during genuine fasting, leading to greater improvements in healthspan and longevity than rapamycin alone.

Rationale

Rapamycin suppresses mTORC1 but does not raise AMP:ATP ratios, so AMPK stays inactive [1]. Genuine fasting activates AMPK, which drives mitochondrial biogenesis, ketogenesis, and autophagy while also inhibiting mTORC1 [2]. Transcriptomic overlap between calorie restriction and rapamycin is limited, with many fasting‑specific genes missing after rapamycin treatment [3]. Chronic rapamycin can impair mTORC2, causing insulin resistance and glucose intolerance, the opposite of fasting‑induced insulin sensitivity [4]. Senescent cells often retain mTORC1 activity despite low nutrients because amino‑acid sensing is broken; AMPK‑dependent lysosomal re‑positioning is required to overcome this block [5]. Therefore, rapamycin alone impersonates scarcity without triggering the adaptive metabolic program that confers fasting’s full benefits.

Predictions

• Mice receiving rapamycin plus an AMPK activator will show higher β‑hydroxybutyrate levels, lower fasting insulin, and increased PGC‑1α expression compared with rapamycin‑only mice.
• The combination will reduce senescent cell burden (p16^INK4a^ positive cells) more effectively than rapamycin alone, as measured by immunostaining and SASP cytokine profiling.
• Healthspan metrics—grip strength, lean‑mass fraction, and cerebral blood flow—will be superior in the combo group, matching or exceeding those seen in alternate‑day fasting cohorts.
• Lifespan extension will be additive: combo‑treated mice will outlive both rapamycin‑only and fasting groups by a statistically significant margin.

Experimental Design

• Use male C57BL/6J mice, aged 4 months. Four groups (n=30 per group): control, rapamycin (14 ppm diet), AMPK activator (metformin 0.1 % w/v in drinking water), and rapamycin + metformin.
• Monitor food intake, body weight, and glucose tolerance every 4 weeks.
• Collect blood at 3, 6, 12, and 18 months for ketones, insulin, and AMPK‑pThr172 levels.
• At 18 months, perform tissue harvest for mTORC1 activity (p‑S6K), mTORC2 activity (p‑AKT‑S473), autophagy markers (LC3‑II), and mitochondrial content (Citrate synthase activity).
• Assess senescence via p16 immunostaining in liver, kidney, and brain; quantify SASP via ELISA.
• Healthspan tests: grip strength, EchoMRI body composition, and MRI‑based cerebral perfusion at 12 and 18 months.
• Survival monitored until natural death.

Potential Outcomes

If the hypothesis is correct, the combo group will exhibit the fasting‑like biomarker profile, superior healthspan, and maximal lifespan. If rapamycin + metformin fails to improve any of these measures over rapamycin alone, the hypothesis is falsified, suggesting that mTORC1 inhibition alone is sufficient for longevity benefits and that AMPK activation does not add value.